Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SURMOUNT-5 (head-to-head)

SURMOUNT-5 (head-to-head)

Tirzepatide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
obesity
Official title
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Sponsor
Eli Lilly and Company
Phase
3b
Registry status
completed · 2023-04 → 2024-11
Participants
751
Duration
72 weeks
Registry
NCT05822830

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
tirzepatide 10/15 mg vs semaglutide 2.4 mg: −13.7 %; treatment discontinuation 21.3 %obesity72751−21.6 %−20.2 %—6.118.443.615.04.8−10.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (8)
  • tirzepatide 10/15 mg · weight_eff · Figure 2A (efficacy estimand, week 72; text-extracted end-po
    −15.4 −21.6
  • tirzepatide 10/15 mg · weight_tp · Results, Change in Body Weight; Table 2
    The least-squares mean percent change in body weight from baseline to week 72 was −20.2% with tirzepatide (95% confidence interval [CI], −21.4 to −19.1)
  • tirzepatide 10/15 mg · ae_dc · Table 3
    Discontinuation of the trial treatment because of adverse events 23 (6.1)
  • tirzepatide 10/15 mg · nausea · Table 3
    Nausea 163 (43.6)
  • tirzepatide 10/15 mg · vomiting · Table 3
    Vomiting 56 (15.0)
  • tirzepatide 10/15 mg · sae · Table 3
    Serious adverse events 18 (4.8)
  • tirzepatide 10/15 mg · sbp · Results, Change in Waist Circumference and Cardiometabolic R
    Systolic blood pressure showed improvements with tirzepatide (least-squares mean change, −10.2 mm Hg; 95% CI, −11.4 to −8.9)
  • tirzepatide 10/15 mg · disc_any · Results, Participants (computed 100−81.6)
    80.2% completed the 72 weeks of trial treatment (81.6% in the tirzepatide group and 78.7% in the semaglutide group)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SURMOUNT-5 (head-to-head). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.